ライフサイエンスコーパス: C-type natriuretic peptide

1 s to DEA/NO, atrial natriuretic peptide, and C-type natriuretic peptide.

2 t of recent advances with a special focus on C-type natriuretic peptide.

3 C-type natriuretic peptide activation of guanylyl cyclas

4 tic peptide acts primarily on the artery and C-type natriuretic peptide acts predominantly on the vei

5 rophy and pathologic calcification, and with C-type natriuretic peptide, an essential factor in endoc

6 om these vessels, the pattern of response to C-type natriuretic peptide and atrial natriuretic peptid

7 donors was mimicked by 2 cGMP analogues and C-type natriuretic peptide and blocked by a specific inh

8 racrine signaling by extracellular peptides (C-type natriuretic peptide and EGF receptor ligands) mai

9 r affinity for [125I]-DNP binding sites than C-type natriuretic peptide and the natriuretic peptide r

10 Atrial natriuretic peptide (ANP), C-type natriuretic peptide, and C-ANP-(4-23), a ligand f

11 pulmonary vasculature to atrial, B-type, and C-type natriuretic peptides (ANP, BNP, and CNP) during a

12 C-type natriuretic peptide attenuated CCh-induced contra

13 C-type natriuretic peptide binding to natriuretic peptid

14 C-type natriuretic peptide (CNP) antagonizes FGFR3 downs

15 ions of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) are elaborated by membr

16 We have recently identified C-type natriuretic peptide (CNP) as an endothelium-deriv

17 C-type natriuretic peptide (CNP) binds the guanylyl cycl

18 ently, CD-NP, a chimeric peptide composed of C-type natriuretic peptide (CNP) fused to the C-terminal

19 In epineurial arterioles, C-type natriuretic peptide (CNP) has properties consiste

20 te important roles for nitric oxide (NO) and C-type natriuretic peptide (CNP) in the regulation of ca

21 Both atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) increased the accumulat

22 C-type natriuretic peptide (CNP) is a member of the natr

23 C-type natriuretic peptide (CNP) is a new member of this

24 C-type natriuretic peptide (CNP) is a newly discovered f

25 C-type natriuretic peptide (CNP) is a vasodilator produc

26 We tested the hypothesis that C-type natriuretic peptide (CNP) mediates coronary vasod

27 he binding of atrial natriuretic peptide and C-type natriuretic peptide (CNP) to the guanylyl cyclase

28 be coimmunoprecipitated with Galpha(i), and C-type natriuretic peptide (CNP) treatment induced trans

29 domain of the mammalian receptor (GC-B) for C-type natriuretic peptide (CNP) was fused to the cataly

30 uced by atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), activators of particul

31 ial-specific deletion of Nppc, which encodes C-type natriuretic peptide (CNP), and determined that th

32 zed for angiotensin-converting enzyme (ACE), C-type natriuretic peptide (CNP), and nitric oxide.

33 Activating mutations in the receptor for C-type natriuretic peptide (CNP), guanylyl cyclase B (GC

34 C-type natriuretic peptide (CNP), in contrast, caused ha

35 GMP signaling pathway composed of the ligand C-type natriuretic peptide (CNP), its receptor, the guan

36 r S-nitroso-N-acetylpenicillamine (SNAP) and C-type natriuretic peptide (CNP), reduced TNF-alpha-indu

37 t marked elevations of cyclic GMP induced by C-type natriuretic peptide (CNP), the ligand of GC-B, bl

38 ngest candidate therapy employs an analog of C-type natriuretic peptide (CNP), which antagonizes the

39 receptor 2 (NPR2) in response to the agonist C-type natriuretic peptide (CNP).

40 vascular and antiproliferative properties of C-type natriuretic peptide (CNP).

41 rom GTP on binding its extracellular ligand, C-type natriuretic peptide (CNP).

42 s a single transmembrane receptor that binds C-type natriuretic peptide (CNP).

43 in the brains of postnatal animals is atrial C-type natriuretic peptide (CNP).

44 lase, respectively, by nitric oxide (NO) and C-type natriuretic peptide (CNP).

45 Neither did C-type natriuretic peptide (CNP, 10, 100, 500 or 1000 pm

46 Increased concentrations of C-type natriuretic peptide could contribute to venous po

47 Later, levels of the NPR2 agonist C-type natriuretic peptide decrease in the follicle, and

48 C-type natriuretic peptide-dependent increases of guanyl

49 r B (NPR-B) stimulates long bone growth in a C-type natriuretic peptide-dependent manner.

50 ic peptides, atrial natriuretic peptide, and C-type natriuretic peptide evoked fluorescence resonance

51 markedly increased by natriuretic peptides (C-type natriuretic peptide >> atrial natriuretic peptide

52 muscle cells cultured from these vessels to C-type natriuretic peptide in comparison with atrial nat

53 CNP (C-type natriuretic peptide) inhibits myofibrogenesis and

54 ocytochemically localized atrial, brain, and C-type natriuretic peptide-like immunoreactivity (ANP-LI

55 L658F, Y708C, R776W, and G959A) bound (125)I-C-type natriuretic peptide on the surface of cells but f

56 clase B is the receptor for a small peptide (C-type natriuretic peptide) produced locally in many dif

57 In H69 cells, atrial and C-type natriuretic peptides stimulated production of cGM

58 l value) was more effective than 1 microM of c-type natriuretic peptide (three-fold increase in cycli

59 se with the discovery that administration of C-type natriuretic peptide to achondroplastic mice ameli

60 by daily injection of a recombinant form of C-type natriuretic peptide to post-natal pups for 18 day

61 ase in cyclic GMP in response to 1 microM of C-type natriuretic peptide vs. six-fold increase in cycl

62 In segments of intact saphenous vein, C-type natriuretic peptide was significantly more effect

63 the order ANP > brain natriuretic peptide >> C-type natriuretic peptide) was also similar to that of

64 Finally, C-type natriuretic peptide, which did not modulate TG ac